Bertolani Mariabeatrice, de Felici Del Giudice Maria Beatrice, Ridolo Erminia, Pucciarini Francesco, Feliciani Claudio, Satolli Francesca
Section of Dermatology, Department of Medicine and Surgery.
Medicine and Surgery Department, Allergy and Clinical Immunology, University of Parma, Italy.
Dermatol Reports. 2022 Jul 12;14(3):9376. doi: 10.4081/dr.2022.9376. eCollection 2022 Sep 14.
Since the beginning of the covid-vaccine campaign, a lot of local and systemic dermatologic reactions happening after the administration of Coronavirus disease 2019 (COVID-19) vaccines have been described, even if their exact biological mechanism is still debated. In this paper we report 4 cases of cutaneous manifestations arose within ten days after the first dose of messenger RNA (mRNA)-based COVID-19 vaccination: one case of giant urticaria, one case of head and neck redness and two cases of Erythema Multiforme (EM). In our experience these reactions were mild, transient and all of them resolved, not recurring after the second dose, so these manifestations shouldn't be considered as an absolute contraindication to the second dose of vaccine, that to date is fundamental.
自新冠疫苗接种运动开始以来，已有许多关于2019冠状病毒病（COVID-19）疫苗接种后发生的局部和全身性皮肤反应的描述，尽管其确切的生物学机制仍存在争议。在本文中，我们报告了4例在接种第一剂基于信使核糖核酸（mRNA）的COVID-19疫苗后十天内出现的皮肤表现病例：1例巨大荨麻疹、1例头颈部发红和2例多形红斑（EM）。根据我们的经验，这些反应是轻微的、短暂的，并且都已消退，在接种第二剂后未复发，因此这些表现不应被视为接种第二剂疫苗的绝对禁忌证，而第二剂疫苗在目前至关重要。
